A multicomponent nanosystem for capturing circulating tumor cells from cancer patients with PD-L1 as an immunotherapy oncotarget

Ganesh Khutale; Saloni Andhari; Rituja Gupta; Gourishankar Aland; Shashwat Banerjee; Kiran Todkar; Milind Pore; Vrushali Khobragade; Alain D'Souza; Narendra Kale; Aravindan Vasudevan; Atul Bharde; Sreeja Jayant; Yuvraj Patil; Jayant Khandare

doi:10.1039/d4tb01360c

A multicomponent nanosystem for capturing circulating tumor cells from cancer patients with PD-L1 as an immunotherapy oncotarget

J Mater Chem B. 2024 Sep 30. doi: 10.1039/d4tb01360c. Online ahead of print.

Authors

Ganesh Khutale^{1

2}, Saloni Andhari^{1

2}, Rituja Gupta³, Gourishankar Aland¹, Shashwat Banerjee¹, Kiran Todkar¹, Milind Pore¹, Vrushali Khobragade¹, Alain D'Souza^{1

2}, Narendra Kale⁴, Aravindan Vasudevan¹, Atul Bharde², Sreeja Jayant¹, Yuvraj Patil³, Jayant Khandare^{1

2

3

5

6}

Affiliations

¹ Actorius Innovations and Research, Pune 411057, India. [email protected].
² OneCell Diagnostics, Pune 411057, India.
³ School of Health Sciences and Technology, Dr Vishwanath Karad MIT World Peace University, Kothrud, Pune 411038, India.
⁴ Center for Nanomedicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA.
⁵ Actorius Innovations and Research, Simi Valley, CA 93063, USA.
⁶ School of Consciousness, Dr Vishwanath Karad MIT World Peace University, Kothrud, Pune 411038, India.

PMID: 39348156
DOI: 10.1039/d4tb01360c

Abstract

Capturing circulating tumor cells (CTCs) from the peripheral blood of cancer patients, where they are disseminated among billions of other blood cells, is one of the most daunting challenge. We report OncoDiscover®, a multicomponent nano-system consisting of iron oxide (Fe₃O₄) nanoparticles (NPs), polyamidoamine generation 4 dendrimers (PAMAM-G4-NH₂), graphene oxide (GO) sheets and an anti-epithelial cell adhesion molecule (anti-EpCAM) antibody (Fe-GSH-PAMAM-GO-EpCAM) for the selective and precise capture of CTCs. We further evaluated this system for therapeutically important oncotargets, exemplifying overexpression of the programmed death ligand 1 (PD-L1) as a functional assay on CTCs in cancer patients. We retrospectively evaluated 134 cancer patients for the presence of CTCs and 113 (84%) showed the presence of CTCs. About 62 (55%) of the CTC +ve patients showed CTCs with PD-L1 expression. The personalized cancer detection demonstrated by the OncoDiscover® CTC analysis tool is highly relevant for cancer monitoring and treatment outcomes.